Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Key Stats

• Today's Range: $14.40 to $15.35
• 50-Day Range: $10.05 to $19.55
• 52-Week Range: $8.89 to $24.50
• Volume: 1.05 million shs
• Average Volume: 524,470 shs
• Market Capitalization: $653.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.44
• Consensus Rating: Moderate Buy

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 at the start of the year. Since then, BBNX shares have decreased by 36.7% and is now trading at $15.07.
View the best growth stocks for 2025 here.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.01.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an initial public offering (IPO) on Thursday, January 30th 2025. The company issued 12,000,000 shares at a price of $17.00 per share.

When does Beta Bionics' lock-up period expire?

Beta Bionics's lock-up period expires on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its initial public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Beta Bionics' major shareholders?

Beta Bionics' top institutional shareholders include Eventide Asset Management LLC (11.37%), Wellington Management Group LLP (9.00%), Sands Capital Ventures LLC (7.16%) and Omega Fund Management LLC (4.59%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider and Mark Hopman.
View institutional ownership trends.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.44
• High Stock Price Target: $30.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +55.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.88
• Quick Ratio: 14.93

Sales & Book Value

• Annual Sales: $65.12 million
• Price / Sales: 10.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.72) per share
• Price / Book: -2.63

Miscellaneous

• Outstanding Shares: 43,360,000
• Free Float: N/A
• Market Cap: $653.44 million
• Optionable: N/A
• Beta: N/A